Inflammatory bowel disease (IBD) comprises 2 distinct entities, ulcerative colitis and Crohn’s disease. Primary care practitioners need to identify early signs and symptoms to appropriately diagnose these conditions in patients to ensure prompt intervention, initiation of therapy, and applicable referral to specialist care. Patients with IBD require vaccination, symptom and therapeutic monitoring, and optimal preventive care, including cancer screenings. In this activity, an IBD specialist provides expert advice on how to manage the spectrum of IBD through diagnosis and long-term patient care.
eNewsletter with interactive benchmarking and video commentary
After completing this activity, participants should be better able to:
- Identify early signs and symptoms of IBD in order to optimize its recognition in patients
- Utilize available data and recommendations to identify effective IBD treatment plans
- Implement recommended long-term patient care methodologies for IBD
NPs and PAs
Joint Accreditation Statement
In support of improving patient care, Practicing Clinicians Exchange is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
ANCC Credit Designation
Nursing contact hours: 1.00, which includes 1.00 hour of pharmacology credit
AAPA Credit Designation
Practicing Clinicians Exchange has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit. Approval is valid until October 28, 2022. PAs should only claim credit commensurate with the extent of their participation.
PA course advisor: Lawrence Herman, DMSc, MPA, PA-C, University of Lynchburg, Lynchburg, Virginia
IPCE Credit Designation
This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.
This program was cosupported by educational grants from AbbVie Inc.; Astellas; Genentech, a member of the Roche Group; Novo Nordisk; Regeneron; and Urovant Sciences, Inc.
This activity is supported by an educational grant from AbbVie Inc.
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.
All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange (PCE) are required to disclose to the audience all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PCE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
Ms Norton: consulting fees: AbbVie, Bristol Myers Squibb, Takeda.
Dr Herman: fees for non-CME/CE services: Novo Nordisk.
None of the members of the Planning Committee or PCE staff have any relevant relationships to disclose, except Dr Herman as noted above.
Participants wishing to earn CE/CME credit must:
- Review the content in its entirety
- Relate the content material to the learning objectives
- Complete the post-test and evaluation form
Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of at least 67%.
The estimated time to complete this activity is 1.00 hour.
Release date: October 29, 2021
Expiration date: October 28, 2022
© 2021 Practicing Clinicians Exchange. All Rights Reserved. 102221C-7C